Ace inhibitors vs angiotensin receptor blockers
Pro Research Analysisby 
Searched over 200M research papers
Comparative Effectiveness of ACE Inhibitors vs Angiotensin Receptor Blockers for Hypertension
Large-scale studies and meta-analyses show that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are equally effective as first-line treatments for hypertension. Both drug classes provide similar protection against major cardiovascular events, including heart attack, heart failure, and stroke, with no significant difference in overall cardiovascular outcomes or mortality rates between them Chen2021Ricci2016Li2014+3 MORE.
Safety and Tolerability: ACE Inhibitors vs ARBs
While both ACE inhibitors and ARBs are effective, ARBs consistently demonstrate a better safety and tolerability profile. Patients taking ARBs experience fewer side effects such as cough and angioedema, which are more common with ACE inhibitors due to their effect on bradykinin metabolism Chen2021Li2014Cutrell2023+1 MORE. This improved tolerability leads to fewer withdrawals from treatment with ARBs compared to ACE inhibitors Li2014Bangalore2016.
Cardiovascular Outcomes in High-Risk Patients
In patients at high cardiovascular risk but without heart failure, both ACE inhibitors and ARBs show similar effectiveness in preventing cardiovascular death, myocardial infarction, and stroke. There is no evidence of statistical superiority for either class in reducing all-cause death, new-onset heart failure, or new-onset diabetes Ricci2016Bangalore2016Gillespie2005.
Use in Special Populations: Diabetes and Kidney Disease
Both ACE inhibitors and ARBs reduce the risk of developing new-onset type 2 diabetes, and their benefits are maintained across different patient groups, including those with hypertension, coronary artery disease, or heart failure . In diabetic nephropathy, both drug classes help reduce proteinuria and slow the decline of kidney function .
Other Clinical Uses: Migraine Prophylaxis
ACE inhibitors and ARBs have also shown promise in reducing the frequency of migraine attacks. While not recommended as first-line agents for migraine prevention, they may be useful in patients who also have hypertension or other comorbidities Dorosh2019Dorosch2019.
Clinical Recommendations and Guidelines
Current guidelines recommend both ACE inhibitors and ARBs as first-line options for hypertension management. However, due to the lower risk of side effects, ARBs are often preferred, especially for patients who experience cough or angioedema with ACE inhibitors Chen2021Sobhy2024Cutrell2023.
Conclusion
ACE inhibitors and ARBs are equally effective for lowering blood pressure and preventing major cardiovascular events. ARBs offer a better safety and tolerability profile, making them a preferred choice for many patients, especially those who cannot tolerate ACE inhibitor side effects. Both classes are valuable in managing hypertension and related conditions, with ARBs often favored for their improved patient comfort and adherence.
Sources and full results
Most relevant research papers on this topic